HDAC Inhibitors Market Forecast (2026–2030): Expansion Trends
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Histone Deacetylase (HDAC) Inhibitors Market During 2026–2030?
The histone deacetylase (hdac) inhibitors market has shown strong expansion in recent years. It is projected to grow from $1.32 billion in 2025 to $1.42 billion in 2026, with a compound annual growth rate (CAGR) of 7.5%. This historical growth can be linked to factors such as increased oncology drug research activity, a greater understanding of epigenetic mechanisms, the expansion of clinical trial programs, rising pharmaceutical R&D investments, and the availability of advanced molecular screening tools.
The histone deacetylase (hdac) inhibitors market size is forecast to experience robust expansion over the next few years, projected to achieve $1.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period stems from factors such as the increasing adoption of personalized cancer therapies, rising investments in epigenetic drug development, an expansion of neurology-related hdac research, a growing demand for targeted therapeutics, and increasing regulatory approvals for novel hdac inhibitors. Significant trends expected during this period include a heightened focus on targeted epigenetic therapies, the rising development of selective hdac inhibitors, an expanding use of combination oncology treatments, the enlargement of precision medicine drug pipelines, and an enhanced emphasis on biomarker-driven drug discovery.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Histone Deacetylase (HDAC) Inhibitors Market Expansion?
The increasing occurrence of neurodegenerative disorders is anticipated to propel the expansion of the histone deacetylase (HDAC) inhibitors market moving forward. These conditions, which involve the progressive degeneration and death of neurons in the brain and spinal cord, result in cognitive and motor dysfunction and include diseases such as Alzheimer’s, distinguished by memory loss and cognitive decline due to amyloid plaques and tau tangles. The growing incidence of neurodegenerative disorders can be attributed to several factors, including age, longevity, genetics, and environmental influences. Histone deacetylase (HDAC) inhibitors are being investigated as potential treatments for neurodegenerative disorders because of their capacity to modulate gene expression and provide neuroprotective effects. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, an estimated 6.7 million older adults in the United States are currently living with Alzheimer’s disease, a number that is projected to rise to nearly 14 million by 2060. Therefore, the rising incidence of neurodegenerative disorders is driving the growth of the histone deacetylase (HDAC) inhibitors market.
Which Segment Types Are Examined In The Histone Deacetylase (HDAC) Inhibitors Market Segment Study?
The histone deacetylase (hdac) inhibitors market covered in this report is segmented –
1) By Class: Class I HDACs, Class II HDACs, Class III HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users
Subsegments:
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
What Emerging Trends Are Seen In The Histone Deacetylase (HDAC) Inhibitors Market?
Leading firms within the histone deacetylase (HDAC) inhibitors market are concentrating their efforts on creating novel remedies, including HDAC inhibitors for the management of cancer, with the goal of improving their effectiveness and minimizing adverse reactions. These inhibitors represent a category of pharmaceutical agents employed in oncology. Their mechanism involves impeding the function of HDAC enzymes, which are responsible for cleaving acetyl groups from histone proteins. This impediment subsequently results in elevated histone acetylation, thereby modifying chromatin architecture and impacting gene expression. An illustrative example occurred in September 2023, when Shuttle Pharmaceuticals Holdings Inc., a US-based entity specializing in pioneering cancer therapies, secured New HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These cutting-edge inhibitors are specifically engineered to home in on particular HDAC enzymes involved in the advancement of cancer, intending to disrupt irregular gene expression profiles that fuel tumor proliferation and spread. The patented compounds exhibit superior potency and selectivity, which helps in reducing unintended effects and boosting the safety records for individuals receiving therapy.
Which Players Are Part Of The Competitive Landscape Of The Histone Deacetylase (HDAC) Inhibitors Market?
Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Get The Full Histone Deacetylase (HDAC) Inhibitors Market Report:
Which Region Leads The Histone Deacetylase (HDAC) Inhibitors Market In Terms Of Market Share?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Histone Deacetylase (HDAC) Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Histone Deacetylase (HDAC) Inhibitors Market 2026, By The Business Research Company
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Histone Deacetylase Inhibitors Market Report 2026
Kinase Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
